Literature DB >> 14574064

Defects in cAMP-pathway may initiate carcinogenesis in dividing nerve cells: a review.

K N Prasad1, W C Cole, X-D Yan, P Nahreini, B Kumar, A Hanson, J E Prasad.   

Abstract

The mechanisms of carcinogenesis in nervous tissues are not well understood. It is now established that adenosine 3,',5'-cyclic monophosphate (cAMP)-pathway plays a crucial role in initiating differentiation in transformed and embryonic cells of neuronal and glial origin. Therefore, we propose that defects in the cAMP-pathway may initiate the first phase of carcinogenesis (immortalization). Subsequent genetic abnormalities in oncogenes, anti-oncogenes or other cellular genes individually or in combination may lead to transformation (cancer phenotype). This hypothesis is derived from the fact that an elevation of the cAMP level in murine NB cells induces terminal differentiation in many of these cells in spite of the fact that they are highly aneuploid. Additional changes in cAMP-regulated genes responsible for initiating differentiation may make these cells resistant to cAMP or may make the cAMP-effect on differentiation reversible. Indeed, cAMP-resistant cells exist in NB cell populations, and the cAMP-effect on differentiation is reversible in glioma cells. Identification of genes that initiate, promote and maintain terminal differentiation and those which prevent differentiation following elevation of cAMP in NB cells may increase our understanding of the mechanisms of carcinogenesis. This review illustrates the following: (a) historical background leading to the discovery of cAMP as an inducer of differentiation in nerve cells; (b) identification of potential sites in cAMP-pathway that may play a crucial role in initiating the first phase of carcinogenesis (immortalization) and potential gene targets in immortalized cells whose alterations may cause neoplastic transformation of nerve cells. It is interesting to note that the cAMP pathway remains responsive to an elevated cAMP level in inducing differentiation in NB cells in spite of chromosomal anomalies and genetic changes associated with the maintenance of a cancer phenotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14574064     DOI: 10.1023/A:1026179324295

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  14 in total

1.  Metab2MeSH: annotating compounds with medical subject headings.

Authors:  Maureen A Sartor; Alex Ade; Zach Wright; David States; Gilbert S Omenn; Brian Athey; Alla Karnovsky
Journal:  Bioinformatics       Date:  2012-04-06       Impact factor: 6.937

Review 2.  Optical approaches for single-cell and subcellular analysis of GPCR-G protein signaling.

Authors:  Dinesh Kankanamge; Kasun Ratnayake; Kanishka Senarath; Mithila Tennakoon; Elise Harmon; Ajith Karunarathne
Journal:  Anal Bioanal Chem       Date:  2019-03-30       Impact factor: 4.142

3.  Aberrant cAMP metabolism in NF1 malignant peripheral nerve sheath tumor cells.

Authors:  Ian Dang; George H De Vries
Journal:  Neurochem Res       Date:  2011-03-05       Impact factor: 3.996

4.  Protein kinase A regulatory subunit distribution in medulloblastoma.

Authors:  Carla Mucignat-Caretta; Luca Denaro; Marco Redaelli; Domenico D'Avella; Antonio Caretta
Journal:  BMC Cancer       Date:  2010-04-14       Impact factor: 4.430

5.  Selective distribution of protein kinase A regulatory subunit RII{alpha} in rodent gliomas.

Authors:  Carla Mucignat-Caretta; Andrea Cavaggioni; Marco Redaelli; Manuela Malatesta; Carlo Zancanaro; Antonio Caretta
Journal:  Neuro Oncol       Date:  2008-08-14       Impact factor: 12.300

6.  Induction of cell cycle arrest at G1 and S phases and cAMP-dependent differentiation in C6 glioma by low concentration of cycloheximide.

Authors:  Xijun Liu; Jin-Ming Yang; Samuel S Zhang; Xin-Yuan Liu; David X Liu
Journal:  BMC Cancer       Date:  2010-12-15       Impact factor: 4.430

7.  Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma.

Authors:  Agnes Rasmuson; Anna Kock; Ole Martin Fuskevåg; Björn Kruspig; Jaione Simón-Santamaría; Vladimir Gogvadze; John Inge Johnsen; Per Kogner; Baldur Sveinbjörnsson
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

8.  ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma.

Authors:  Tony Huynh; Murray D Norris; Michelle Haber; Michelle J Henderson
Journal:  Front Oncol       Date:  2012-12-19       Impact factor: 6.244

9.  Protein kinase a in cancer.

Authors:  Antonio Caretta; Carla Mucignat-Caretta
Journal:  Cancers (Basel)       Date:  2011-02-28       Impact factor: 6.639

10.  An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.

Authors:  Daniela Formicola; Giuseppe Petrosino; Vito Alessandro Lasorsa; Piero Pignataro; Flora Cimmino; Simona Vetrella; Luca Longo; Gian Paolo Tonini; André Oberthuer; Achille Iolascon; Matthias Fischer; Mario Capasso
Journal:  J Transl Med       Date:  2016-05-17       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.